DGAP-News: Fresenius Medical Care AG & Co. KGaA Sets New Long-Term Revenue Target and Outlines Vision for 2020 at Capital

DGAP-News: Fresenius Medical Care AG & Co. KGaA Sets New Long-Term Revenue 
Target and Outlines Vision for 2020 at Capital Markets Day 2014

DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s):
Fresenius Medical Care AG & Co. KGaA Sets New Long-Term Revenue Target
and Outlines Vision for 2020 at Capital Markets Day 2014

04.04.2014 / 08:28


Bad Homburg, Germany - Fresenius Medical Care AG & Co. KGaA (the "company"
or "Fresenius Medical Care"; Frankfurt Stock Exchange: FME / New York Stock
Exchange: FMS), the world's largest provider of dialysis products and
services, hosted a Capital Markets Day (CMD) on April 3 in New York.

The event was aimed at giving analysts and investors further insight into
Fresenius Medical Care's vision for 2020 and the growth and efficiency
strategies the company is pursuing. The CMD included presentations by chief
executive officer Rice Powell and other members of the senior management
team on global strategy, regional business strategies, R&D, manufacturing,
medical therapy and financials.

Long-term financial target
Fresenius Medical Care also announced its long-term financial target for
2020. Based on revenue of $14.6 billion in fiscal year 2013, the company
has set its ambitious revenue guidance for 2020 at $28 billion. This
represents a cumulative average growth rate of around 10% per annum (CAGR)
and a near doubling of revenue compared to 2013.

Global Efficiency Program
Participants at the CMD received an update on the company's Global
Efficiency Program. The program's objectives are to identify efficiency
potential, enhance the overall competitiveness of Fresenius Medical Care,
and free up resources for reinvestment. The company has several projects in
place that will achieve sustained efficiency gains over multiple years and
should lead to cost savings of $300 million per annum by 2017.

Continued strong growth in dialysis products and services
Fresenius Medical Care's world-leading position in the dialysis industry
has been built on its vision and capabilities in developing innovations
that shape the future of treatment for patients. Fresenius Medical Care
will continue to develop innovative products focused on quality outcomes
for the patient while expanding the company's dialysis products and
services around the world.

Extending care coordination for patients
In addition to strong growth in the underlying business of dialysis
products and services, Fresenius Medical Care sees significant potential in
a business area it began developing some years ago and now calls Care
Coordination. Care Coordination is an extension of the company's renal care
for its patients and currently includes e.g. vascular care, laboratory and
pharmacy businesses. Fresenius Medical Care plans to build this business
segment and expects revenue from Care Coordination to grow from 3% of total
revenue in 2013 to about 18% in 2020.

Rice Powell, chief executive officer of Fresenius Medical Care, commented
at the CMD: "The number of dialysis patients is expected to double in the
next seven years. We will continue to execute on our plan for growth and
efficiency across the business. Our vertically integrated business enables
us to provide the most effective and efficient care for these patients and
is the platform to expand our care coordination capabilities. We recognize
that moving beyond our core dialysis product and services business brings
areas with different risk and margin profiles, and we are convinced this is
reflected in our vision and guidance for 2020. With the acceleration in our
revenue growth going forward we should be able to generate earnings after
tax growth in the high single digits."

PDF versions of presentations and other information material given at the
Capital Markets Day can be found on our website:

Fresenius Medical Care is the world's largest integrated provider of
products and services for individuals undergoing dialysis because of
chronic kidney failure, a condition that affects more than 2.5 million
individuals worldwide. Through its network of 3,250 dialysis clinics in
North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius
Medical Care provides dialysis treatments for 270,122 patients around the
globe. Fresenius Medical Care is also the world's leading provider of
dialysis products such as hemodialysis machines, dialyzers and related
disposable products.

For more information about Fresenius Medical Care, visit the company's
website at www.fmc-ag.com.

This release contains forward-looking statements that are subject to
various risks and uncertainties. Actual results could differ materially
from those described in these forward-looking statements due to certain
factors, including changes in business, economic and competitive
conditions, regulatory reforms, foreign exchange rate fluctuations,
uncertainties in litigation or investigative proceedings, and the
availability of financing. These and other risks and uncertainties are
detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the
U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co.
KGaA does not undertake any responsibility to update the forward-looking
statements in this release.

End of Corporate News


04.04.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de


Language:    English                                                
Company:     Fresenius Medical Care AG & Co. KGaA                   
             Else-Kröner-Straße 1                                   
             61352 Bad Homburg                                      
Phone:       +49 (0) 6172- 609 2525                                 
Fax:         +49 (0) 6172- 609 2301                                 
E-mail:      ir@fmc-ag.com                                          
Internet:    www.fmc-ag.de                                          
ISIN:        DE0005785802, DE0005785836,                            
WKN:         578580, 578583                                         
Indices:     DAX                                                    
Listed:      Regulierter Markt in Frankfurt (Prime Standard);       
             Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,  
             München, Stuttgart; Terminbörse EUREX; NYSE            
End of News    DGAP News-Service  
261618 04.04.2014                                                      
Press spacebar to pause and continue. Press esc to stop.